Drug Profile
Research programme: vitamin D receptor agonists - Eli Lilly and Company
Alternative Names: LY-2108491; LY-2109866; VDRM IILatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class
- Mechanism of Action Calcitriol receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neuromuscular disorders; Osteoporosis; Psoriasis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Neuromuscular-disorders in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Osteoporosis in USA (PO)
- 15 Sep 2009 Preclinical trials in Osteoporosis in USA (PO)